Splitting Irritable Bowel Syndrome: From Original Rome to Rome II Criteria

Mearin, Fermı́n; Roset, Montse; Badı́a, Xavier; Balboa, Agustín; Baró, Eva; Ponce, Julio; Dı́az-Rubio, Manuel; Caldwell, Ellen; Cucala, Mercedes; Fueyo, Arturo; Talley, Nicholas J.

doi:10.1046/j.1572-0241.2003.04024.x

Cited by 44 publications

(32 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…42,43 Previous studies have also suggested that agreement between the Rome I and Manning criteria are poor, 41,44 leading some to propose that the Rome criteria are too restrictive. 41 Our findings show that, regardless of attempts to tighten the definition of IBS by refining the symptoms used to diagnose the condition, there is little to choose between the available diagnostic criteria.…”

Section: Discussionmentioning

confidence: 99%

Validation of the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care

et al. 2013

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Validation of the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care

et al. 2013

View full text Add to dashboard Cite

“…Groups consisted of patients with CD, UC, slc, or IBS and healthy controls. The accepted criteria for UC, CD, IBS, and controls were used (5,19,23,31). Slc was defined as a first-time colitis that macroscopically and histologically resembled infectious-like colitis and that had an appearance and histology atypical for IBD.…”

Section: Methodsmentioning

confidence: 99%

Spatial Organization and Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease

et al. 2005

View full text Add to dashboard Cite

The composition and spatial organization of the mucosal flora in biopsy specimens from patients with inflammatory bowel disease (IBD; either Crohn's disease or ulcerative colitis), self-limiting colitis, irritablebowel syndrome (IBS), and healthy controls were investigated by using a broad range of fluorescent bacterial group-specific rRNA-targeted oligonucleotide probes. Each group included 20 subjects. Ten patients who had IBD and who were being treated with antibiotics were also studied. Use of nonaqueous Carnoy fixative to preserve the mucus layer was crucial for detection of bacteria adherent to the mucosal surface (mucosal bacteria). No biofilm was detectable in formalin-fixed biopsy specimens. Mucosal bacteria were found at concentrations greater than 10 9 /ml in 90 to 95% of IBD patients, 95% of patients with self-limiting colitis, 65% of IBS patients, and 35% of healthy controls. The mean density of the mucosal biofilm was 2 powers higher in IBD patients than in patients with IBS or controls, and bacteria were mostly adherent. Bacteroides fragilis was responsible for >60% of the biofilm mass in patients with IBD but for only 30% of the biofilm mass in patients with self-limiting colitis and <15% of the biofilm mass in patients with IBS. In contrast, bacteria which positively hybridized with the probe specific for Eubacterium rectale-Clostridium coccoides accounted for >40% of the biofilm in IBS patients but for <15% of the biofilm in IBD patients. In patients treated with (5-ASA) or antibiotics, the biofilm could be detected with 4,6-diamidino-2-phenylindole but did not hybridize with fluorescence in situ hybridization probes. A Bacteroides fragilis biofilm is the main feature of IBD. This was not previously recognized due to a lack of appropriate tissue fixation. Both 5-ASA and antibiotics suppress but do not eliminate the adherent biofilm.

show abstract

“…The economic review and modelling of the IBS clinical guideline suggests a 45% response rate for placebo as drawn from Mearin et al, 155 which for the base case will be taken to be the response rate to dietary advice. This is broadly in line with the 50% assumed in the YHEC report, 50 which was based on expert opinion.…”

Section: Model Structurementioning

confidence: 99%

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Waugh

Cummins²,

Royle³

et al. 2013

Health Technology Assessment

234

201

View full text Add to dashboard Cite

Splitting Irritable Bowel Syndrome: From Original Rome to Rome II Criteria

Abstract: Many subjects meeting original Rome criteria for IBS do not meet Rome II criteria: approximately one quarter of subjects do not have sufficient symptom duration or frequency to be diagnosed with IBS and almost half are now considered as having other ("major" or "minor") FBD.

Cited by 44 publications

References 31 publications

Validation of the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care

Validation of the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care

Spatial Organization and Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Contact Info

Product

Resources

About